Cargando…
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months
AIMS: The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon‐like pepti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804517/ https://www.ncbi.nlm.nih.gov/pubmed/35876235 http://dx.doi.org/10.1111/dom.14823 |
_version_ | 1784862128062070784 |
---|---|
author | Guerci, Bruno Giorgino, Francesco Sapin, Hélène Boye, Kristina Lebrec, Jérémie Federici, Marco Orsini Heitmann, Elke Dib, Anne Füchtenbusch, Martin García‐Pérez, Luis‐Emilio |
author_facet | Guerci, Bruno Giorgino, Francesco Sapin, Hélène Boye, Kristina Lebrec, Jérémie Federici, Marco Orsini Heitmann, Elke Dib, Anne Füchtenbusch, Martin García‐Pérez, Luis‐Emilio |
author_sort | Guerci, Bruno |
collection | PubMed |
description | AIMS: The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). This manuscript presents 12‐month interim data. MATERIALS AND METHODS: TROPHIES is a prospective, non‐comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide. Data on clinical characteristics, GLP‐1 RA persistence and treatment patterns of glucose‐lowering medication were collected at initiation of first injectable therapy and by 12 months. RESULTS: By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy. Both cohorts presented a high probability [95% confidence interval (CI)] of GLP‐1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)] and reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, −1.18 (−1.27 to −1.08); liraglutide, −1.15 (−1.26 to −1.05)] with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline. Mean weight (95% CI) change from baseline was −3.2 kg (−3.6 to −2.8) for dulaglutide and −3.4 kg (−3.9 to −3.0) for liraglutide. Slight changes in concomitant medications were observed compared with baseline. CONCLUSIONS: In the real‐world setting, dulaglutide and liraglutide cohorts achieved good persistence with similarly improved glycaemic control that was accompanied by weight loss at 12 months, consistent with previous clinical trial results. |
format | Online Article Text |
id | pubmed-9804517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-98045172023-01-03 The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months Guerci, Bruno Giorgino, Francesco Sapin, Hélène Boye, Kristina Lebrec, Jérémie Federici, Marco Orsini Heitmann, Elke Dib, Anne Füchtenbusch, Martin García‐Pérez, Luis‐Emilio Diabetes Obes Metab Original Articles AIMS: The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). This manuscript presents 12‐month interim data. MATERIALS AND METHODS: TROPHIES is a prospective, non‐comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide. Data on clinical characteristics, GLP‐1 RA persistence and treatment patterns of glucose‐lowering medication were collected at initiation of first injectable therapy and by 12 months. RESULTS: By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy. Both cohorts presented a high probability [95% confidence interval (CI)] of GLP‐1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)] and reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, −1.18 (−1.27 to −1.08); liraglutide, −1.15 (−1.26 to −1.05)] with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline. Mean weight (95% CI) change from baseline was −3.2 kg (−3.6 to −2.8) for dulaglutide and −3.4 kg (−3.9 to −3.0) for liraglutide. Slight changes in concomitant medications were observed compared with baseline. CONCLUSIONS: In the real‐world setting, dulaglutide and liraglutide cohorts achieved good persistence with similarly improved glycaemic control that was accompanied by weight loss at 12 months, consistent with previous clinical trial results. Blackwell Publishing Ltd 2022-08-31 2022-12 /pmc/articles/PMC9804517/ /pubmed/35876235 http://dx.doi.org/10.1111/dom.14823 Text en © 2022 Eli Lilly and Company and The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Guerci, Bruno Giorgino, Francesco Sapin, Hélène Boye, Kristina Lebrec, Jérémie Federici, Marco Orsini Heitmann, Elke Dib, Anne Füchtenbusch, Martin García‐Pérez, Luis‐Emilio The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months |
title |
The
Real‐World
Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months |
title_full |
The
Real‐World
Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months |
title_fullStr |
The
Real‐World
Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months |
title_full_unstemmed |
The
Real‐World
Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months |
title_short |
The
Real‐World
Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months |
title_sort |
real‐world
observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (trophies): patient disposition, clinical characteristics and treatment persistence at 12 months |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804517/ https://www.ncbi.nlm.nih.gov/pubmed/35876235 http://dx.doi.org/10.1111/dom.14823 |
work_keys_str_mv | AT guercibruno therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT giorginofrancesco therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT sapinhelene therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT boyekristina therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT lebrecjeremie therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT federicimarcoorsini therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT heitmannelke therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT dibanne therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT fuchtenbuschmartin therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT garciaperezluisemilio therealworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT guercibruno realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT giorginofrancesco realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT sapinhelene realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT boyekristina realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT lebrecjeremie realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT federicimarcoorsini realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT heitmannelke realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT dibanne realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT fuchtenbuschmartin realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months AT garciaperezluisemilio realworldobservationalprospectivestudyofhealthoutcomeswithdulaglutideandliraglutideinpatientswithtype2diabetestrophiespatientdispositionclinicalcharacteristicsandtreatmentpersistenceat12months |